Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes

• Published in: Communications biology 2022-02, Vol.5 (1), p.110-110, Article 110
• Main Authors: Pronier, Elodie, Imanci, Aygun, Selimoglu-Buet, Dorothée, Badaoui, Bouchra, Itzykson, Raphael, Roger, Thierry, Jego, Chloé, Naimo, Audrey, Francillette, Maëla, Breckler, Marie, Wagner-Ballon, Orianne, Figueroa, Maria E., Aglave, Marine, Gautheret, Daniel, Porteu, Françoise, Bernard, Olivier A., Vainchenker, William, Delhommeau, François, Solary, Eric, Droin, Nathalie M.
• Format: Article
• Language: English
• Subjects: 13; 13/21; 38; 42; 42/89; 45; 45/100; 45/15; 45/91; 631/337/100/102; 631/80/304; 82; 82/80; Age; Arteriosclerosis; Biology; Biomedical and Life Sciences; Cardiovascular diseases; Chemokines; Chronic myelomonocytic leukemia; Cytokines; EGR-1 protein; Hemopoiesis; Histones; Human health and pathology; Inflammation; Leukocyte migration; Life Sciences; Macrophage migration inhibitory factor; Monocytes; Mutation; Myeloid cells; Myelomonocytic leukemia; Progenitor cells; Therapeutic applications; Therapeutic targets
• ISSN: 2399-3642; 2399-3642
• DOI: 10.1038/s42003-022-03057-w

Somatic mutation in TET2 gene is one of the most common clonal genetic events detected in age-related clonal hematopoiesis as well as in chronic myelomonocytic leukemia (CMML). In addition to being a pre-malignant state, TET2 mutated clones are associated with an increased risk of death from cardiovascular disease, which could involve cytokine/chemokine overproduction by monocytic cells. Here, we show in mice and in human cells that, in the absence of any inflammatory challenge, TET2 downregulation promotes the production of MIF (macrophage migration inhibitory factor), a pivotal mediator of atherosclerotic lesion formation. In healthy monocytes, TET2 is recruited to MIF promoter and interacts with the transcription factor EGR1 and histone deacetylases. Disruption of these interactions as a consequence of TET2 -decreased expression favors EGR1-driven transcription of MIF gene and its secretion. MIF favors monocytic differentiation of myeloid progenitors. These results designate MIF as a chronically overproduced chemokine and a potential therapeutic target in patients with clonal TET2 downregulation in myeloid cells. To improve our understanding of the pathological role of TET2 mutations, Pronier, Imanci et al. use mice and human cells to show that TET2 downregulation promotes the production of macrophage migration inhibitory factor (MIF). In addition they show that whilst TET2 is recruited to the MIF promoter in healthy monocytes, decreased TET2 expression results in chronic overproduction of MIF - suggesting that MIF signaling could therefore constitute a potential therapeutic target for conditions associated with TET2 mutations.